相关临床试验
7
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
4
57.1%
尚未招募
1
14.3%
招募中
1
14.3%
Unknown
1
14.3%
暂无批准数据
- A global analysis of over 106,000 pediatric infection samples across 82 countries found antibiotic resistance increased in every region between 2004 and 2022. - Gram-negative bacteria Acinetobacter baumannii and Klebsiella are driving resistance, with carbapenem resistance projected to reach 82% and 35% respectively by 2035. - Babies, children in intensive care, and those in low-resource countries are most affected, with resistance rising fastest to WHO-classified 'Watch' and 'Reserve' antibiotics. - Researchers launched the AMR in Kids platform providing country, pathogen, and antibiotic-class forecasts to 2035 to guide treatment decisions and public health planning.
- Kenya became one of the first countries globally to distribute lenacapavir, a twice-yearly injection described as the closest thing yet to an HIV vaccine, offering near-total protection against HIV infection. - The initial rollout covers 21,000 doses across 152 health facilities in 15 high-burden counties, but excludes high-risk informal settlements like Kibera where HIV prevalence reaches 12 percent. - Access barriers including transport costs and distance to approved facilities may limit the drug's reach to vulnerable populations, despite its potential as a game-changer in HIV prevention. - Pricing concerns remain as the drug could cost 7,800 Kenyan shillings annually if scaled up, though agreements aim to reduce costs to £30 per patient by 2027 through generic versions.
- Nigeria has launched the Innovative Cancer Medicine Demonstration Project at National Hospital Abuja, marking the first time advanced cancer immunotherapy will be administered in a structured feasibility study in Sub-Saharan Africa. - The program provides free nivolumab treatment to 30 patients with metastatic colorectal cancer, with full costs estimated at over seven billion naira sponsored by international partners including Bristol Myers Squibb, Roche, and the Parker Institute for Cancer Immunotherapy. - The initiative represents a collaboration between the Federal Government, Clinton Health Access Initiative, and pharmaceutical partners to demonstrate that Nigeria has the infrastructure and expertise to safely deliver advanced cancer treatment. - Success of this feasibility study could pave the way for including immunotherapy in Nigeria's National Health Insurance scheme and establishing cost negotiations for broader access across Africa.
